Cochrane News

Subscribe to Cochrane News feed
Updated: 11 hours 56 min ago

Virtual #CochraneSantiago Meet-up in Malaysia!

Wed, 12/04/2019 - 18:59

There is no one place or office that is 'Cochrane'. Our global network of members and supporters work together to achieve our strategic goals and are usually affiliated to one or more Cochrane Groups based on their interests, expertise, and/or geographical location. This year’s virtual #CochraneSantiago Colloquium embodies this global and collaborative spirt! With five days of content organized around celebrating our diversity, we are gathering together as a Cochrane global community.

Members of Cochrane Malaysia took this as an opportunity to bring some of their members in Malaysia together. On Tuesday 4 December they gathered at two locations brought together by technology. Members met at the RCSI & UCD Malaysia Campus in Penang and at Perdana University in Kuala Lumpur and connected via video conference for a local opening and welcome to the Virtual #CochraneSantiago Colloquium in Malaysia. Then, each team screened the #CochraneSantiago content separately, engaging with the presentations and discussing with their colleagues. They were joined by their College President, David Whitford, who is a Cochrane Metabolic and Endocrine Disorders author.

It is wonderful to see Cochrane Malaysia coming together to share, explore, discuss and learn from the content provided by the Colloquium. All Virtual #CochraneSantiago Colloquium content is freely available to all,  on the Colloquium website.

Wednesday, December 4, 2019

A more rigorous conflict of interest policy is coming for Cochrane

Wed, 12/04/2019 - 11:47

Karla Soares-Weiser, Cochrane Library’s Editor in Chief, outlined a new conflict of interest policy that is forthcoming in 2020 in a BMJ opinion piece. Cochrane is committed to independence, transparency, and integrity in healthcare research and minimizing the impact of conflicts of interest in the conduct of Cochrane Reviews. This commitment is reflected in our current Commercial Sponsorship Policy which not only requires interests to be declared, it also rules that some conflicts will prevent authors from conducting Cochrane Reviews.  Although Cochrane’s current conflict of interest policy is stricter than most journals, we have revisited it recently with the aim of strengthening our approach to financial conflicts of interest and clarifying our position regarding non-financial interests.

Cochrane’s new, more rigorous approach includes the following key changes: 

  1. The proportion of conflict free authors in a team will increase from a simple majority to a proportion of 66% or more. 
  2. Last authors will be treated in the same way as first authors and, therefore, must be entirely free of conflicts.
  3. Authors of industry-funded clinical studies eligible for inclusion in a Cochrane Review will be prohibited from being the first or last author on that review.
  4. Reviews funded by not-for-profit organizations with a specific interest in the outcome will be assessed by Cochrane’s Conflict of Interest Arbiter Panel and the Editor in Chief, who will judge whether the review is conflicted.
  5. Cochrane authors will need to declare non-financial interests and think critically about how these might influence the results of the review.

An important motivation for strengthening our conflict of interest policy is an understanding of how this issue impacts a reader’s trust in the healthcare information they read. As an organization, Cochrane looks forward to the improvements this policy will bring in keeping Cochrane Reviews demonstrably independent and impartial in their reporting and conclusions.

 

 

Wednesday, December 4, 2019

Cochrane author’s work acknowledged in NIHR co-production publication

Tue, 12/03/2019 - 18:50

Cochrane author, and joint Co-ordinating editor, Alex Pollock, of Glasgow Caledonian University has seen her ground-breaking work in co-producing a Cochrane review included in a new UK’s National Institute of Health Research (NIHR) INVOLVE publication.

Alex involved stroke survivors, carers, physiotherapists and educators in an update of a Cochrane systematic review relating to physiotherapy after stroke. Her innovative work was included in Co-production in Action Number Two, as an example of good practice in Co-production, published in November 2019 by INVOLVE. You can hear Alex talk about her work in a webinar recorded ahead of the Cochrane Virtual Colloquium here.

Alex Pollock said “Our team was delighted that NIHR INVOLVE chose to include our example of involving people in our Cochrane review as part of their co-production collection.  I think that this highlights the fact that involving people in systematic reviews is now viewed as being as important as involving people in other areas of research, such as research prioritisation or primary research studies.   Although we don’t yet know the “best” way to involve people in reviews, our work on the ACTIVE project shows that there are some great examples of different ways of successfully involving people in reviews, including examples - like ours - where people have had real and meaningful control over key decisions relating to a review”.

Gary Hickey, of NIHR INVOLVE said” It’s great to see co-production gaining traction in various aspects of research, including Cochrane systematic reviews.  Alex’s example demonstrates how the public can work with researchers and healthcare professionals to analyse and interpret data and disseminate findings, ensuring that systematic reviews are more relevant and accessible.”

Alex’s work led to the ACTIVE project, supported by Cochrane Training and the Cochrane Consumer Network. This included a systematic scoping review aimed to document the evidence-base relating to stakeholder involvement in systematic reviews and to use this evidence to describe how stakeholders have been involved in systematic reviews. This was followed by the development of the ACTIVE framework that provides a structure to describe key components of stakeholder involvement within a systematic review. The ACTIVE framework may support the decision-making of systematic review authors in planning how to involve stakeholders in future reviews. The learning resource Involving People turned this work into guidance for systematic review authors who wish to involve stakeholders in producing their reviews.

the development oftheACTIVE frameworkthat provides a structure to describe key components ofstakeholder involvement within a systematic review. The ACTIVE framework maysupport the decision-making of systematic review authors in planning how toinvolve stakeholders in future reviews. The learning resourceInvolving Peopleturned this work into guidance for systematic review authors who wish to involvestakeholders in producing their reviews. Tuesday, December 3, 2019

Welcome to Virtual Colloquium #CochraneSantiago!

Mon, 12/02/2019 - 11:30

Welcome to Cochrane’s first ever Virtual Colloquium, #CochraneSantiago!

We are delighted to see everyone’s hard work for this Colloquium on display and we look forward to engaging with all of you in this new Colloquium format.

Daily themes

We have so much share with you - vitural posters, recorded oral presentations, and special content!

To help organize the week, we are focusing on daily themes - you can get an overview here. At the top of the website in the blue navigation bar there are tabs for each day. Come to the website each day and engage with the content.

Navigating the content

Special Content videos will premiere at 10:00 Toronto time/12:00 Chilean time/15:00 GMT on YouTube each day this week; check out the daily page to find these videos, links, and participate in the live chat on YouTube!

Links to specific and relevant oral presentation and poster categories are highlighted at the bottom of each page. You can also browse all oral presentations and all posters and filter by categories that interests you.

Available to all

A reminder that you do not have to register or login to the Colloquium site to see Virtual #CochraneSantiago content—all is free, open to all, and available on the website!

Join the conversation by tagging #CochraneSantiago on your social media posts, and follow our content creators to continued the conversation on your preferred social media.

Welcome to Virtual #CochraneSantiago, we are so glad you’re here!

Monday, December 2, 2019

Podcast: Lifestyle changes for treating psoriasis

Thu, 11/28/2019 - 12:54

Psoriasis is a common skin problem and there are several Cochrane Reviews of various ways to treat it. These were added to in July 2019 with the publication of a new review on the potential benefits of lifestyle changes. We asked Professor Ching-Chi Chi from the Chang Gung Memorial Hospital in Taoyuan Taiwan to tell us what they found.

Psoriasis is a chronic inflammatory skin disease. It causes thick, red, itching, and scaling plaques, and affects more than 100 million people worldwide.

Obesity, drinking, smoking, and lack of physical activity may make the condition worse, and we wanted to find out whether changes to these lifestyle factors might help. We were particularly interested in things such as diet and exercise; and although we also wanted to investigate interventions targeting smoking or alcohol consumption; we found no trials on alcohol abstinence or smoking cessation.

We examined the research evidence that was available up to July 2018, and identified 10 relevant randomised trials, with a total of approximately 1,200 participants. The quality of evidence was moderate to low, with study limitations including participants knowing which treatment they were receiving and a large number of withdrawals from the trials.

However, we were able to draw some conclusions. We found that among obese patients with psoriasis, dietary intervention with a low-calorie diet may reduce the severity of psoriasis, and probably improves their quality of life and reduces their body mass index, or BMI. Also, among obese patients with psoriasis, combined low-calorie diet and exercise programme probably reduces the severity of psoriasis and BMI. Generally, participants complied with the assessed lifestyle changes successfully.

When compared to usual care, we found no evidence that education promoting healthy lifestyle alone without explicit dietary intervention or an exercise programme had an effect on the severity of psoriasis.

In summary, among obese patients with psoriasis, a low-calorie diet with or without an exercise programme may improve the severity of psoriasis and probably improves quality of life and BMI. However, whether dietary interventions prolong the time to relapse or whether it is effective in non-obese patients with psoriasis remains unclear.

Thursday, November 28, 2019

Launch of Cochrane Dominican Republic

Thu, 11/28/2019 - 11:55
The Cochrane Library is now available in the Dominican Republic providing high quality, trusted health information for health decision makers.  The new Cochrane affiliate will be located at the Ministry of Health in Santo Domingo and will promote evidence-informed decision making in health care through dissemination of Cochrane evidence and enhancing the capacity to understand and use evidence synthesis in health policy decision-making.
 
Cochrane Dominican Republic joins Cochrane, a global independent network of researchers, professionals, patients, careers and people interested in health. Cochrane works with collaborators from more than 130 countries to produce credible, accessible health information that is free from commercial sponsorship and other conflicts of interest. Cochrane’s work is recognized as representing an international gold standard for high quality, trusted information.
 
Cochrane Dominican Republic is an Affiliate of Cochrane Central America and Spanish speaking Caribbean,  and is part of the Iberoamerican Cochrane Network.
 
The Directors of Cochrane Dominican Republic, Andelys de la Rosa and José Mordan said, “This is a hugely exciting opportunity in the region of the Caribbean. Increasing dissemination and improving the use of the evidence in health care is critical for clinicians, patients, students everywhere in the world, including Dominican Republic. To start, we have arranged for the Cochrane Library to be available across the Dominican Republic from November 2019.”
 
Cochrane’s CEO Mark Wilson, warmly welcomed today’s news, “Cochrane Dominican Republic joins a global collaboration of Cochrane groups involved in creating and presenting Cochrane evidence across the world. It is exciting to see this affiliate join this network with the aim of deepening the scope reach and impact of Cochrane evidence in the Caribbean region.”
 
Xavier Bonfill, Director of Cochrane Iberoamerica, “This new Affiliate is already backed by support from the national academic community and commitments by the Ministry of Health, as well as the global Cochrane community. This strong start is a signal to health decisions makers in Dominican Republic to collaborate with Cochrane in the dissemination and use of health evidence.”
 
On November 29th, Cochrane Dominican Republic will host a launch event bringing together health leaders from across the education and health sector in the Dominican Republic. Friday, November 29, 2019

Counting down to Cochrane’s first ever Virtual #CochraneSantiago - how you can join!

Wed, 11/27/2019 - 16:58

It’s only a few days away - Virtual #CochraneSantiago

Next week is our first Virtual Colloquium and we are delighted to showcase the fabulous work of hundreds of Cochrane contributors.

We look forward to welcoming you Monday 2 December - Friday 6 December and here’s more information on how you can take part and hopefully answer some of your questions:

How do I access Virtual #CochraneSantiago content?

All content will be available on the Colloquium website!  At the top of the home page, there is a menu-tab for each day of the Virtual Colloquium with that day’s theme. On each daily page, you can scroll through to find Special Content (Special and Plenary-style presentations), links to Related Content, highlighted categories of daily Oral Presentations and Posters, and information about how to join the conversation on social media across our SEVEN platforms. Take a look at the content now and check back daily next week.

Do I need to register for the Virtual #CochraneSantiago Colloquium?

No, it’s just about selecting what you want to see and hear. All Virtual Colloquium content is free, open to all, and hosted on the Colloquium website. You will not need to login or need to have a Cochrane ‘account’ to access the content, either. The more global participation, the better!

When will Special Content videos premiere?

Each day, all Special Content videos will premiere at 10:00 Toronto time/12:00 Chilean time/15:00 GMT on YouTube. During the premiering of the video, you can watch on the video’s YouTube page and participate in the live chat happening at the same time. You can go to the daily menu-tabs on the Colloquium website and see what we have planned and even set personal reminders in your YouTube account so that you are notified when they go live. If you are not able to see it at this exact time, no problem, you can watch it any time after it premieres on YouTube or when it’s embedded under the daily menu-tabs on the Colloquium website.

How can I see Colloquium posters and oral presentations?

We have about 180 digital posters and over 100 oral presentations to share with you! Starting on Monday 2 December, all oral presentations will be available here and virtual posters will be available here. You can sort through these pages by abstract category, or scroll through them all! These are also linked on the Colloquium homepage in the Menu “Presentations”, and certain categories of posters and oral presentations will be highlighted for each themed day.

Is there any truly ‘live’ Colloquium content?

Yes! If you are a Cochrane Member, Cochrane’s Annual General Meeting will be held live on Thursday, December 5, from 09:00-10:00 GMT. To register for this live meeting and find out about voting, visit here.

Join the conversation!

As you take part in this unique week of Virtual #CochraneSantiago content, we want to hear from you! We have 40+ International Content Creators who will be actively discussing our content each day and our #CochraneSantiago hashtag will be abuzz on Twitter, Instagram, and other platforms. You can also join the YouTube chat for the launch of Special Content videos. Make your voice heard and help make this Virtual Colloquium as interactive as possible. Finally, a survey will be posted on the Colloquium website and social media on the final day, we will collect your feedback so please get involved and share! Our Virtual Colloquium format is a first for Cochrane, and we want to hear what you think!

See you in just a few days….

Wednesday, November 27, 2019

Featured Review: Reducing uncertainties in choosing first-line treatment in newly diagnosed multiple myeloma

Tue, 11/26/2019 - 12:50

Multiple myeloma is a type of blood cancer. It accounts for approximately 2% of all cancers and is still considered incurable. For people with newly diagnosed multiple myeloma (NDMM), who are unsuitable for a procedure where damaged blood cells are replaced with healthy ones (stem-cell transplant), treatment is usually a multiple drug combination of bortezomib, lenalidomide, or thalidomide, plus melphalan and prednisolone (MP) or dexamethasone (D). Multiple drug combinations are approved for initial anti-myeloma therapy, however, access to these medicines is restricted in many countries worldwide.

The Cochrane Review used network meta-analysis (NMA) to compare the benefits and harms of selected anti-myeloma drugs (bortezomib (V), lenalidomide (R), thalidomide (T)) for transplant-unsuitable NDMM.

The review identified 25 studies involving 11,403 transplant-unsuitable adults with NDMM, and comparing 21 different treatment regimens. It looked at survival, harms and quality of life.

The review concluded that VRDc showed the highest overall survival benefits, compared to MP. RD and TMP also improved OS compared to MP. However, these combinations of drugs also led to more adverse events compared to MP, and led to more people stopping treatment. More trials are needed that look carefully at both harms and quality of life.

The results of this review informed a successful application to the World Health Organization (WHO) Essential Medicines List (EML), which previously had no anti-myeloma medicines included.

The editorial process for this review was managed by the Cochrane Fast-Track Service.

Read the review

Tuesday, November 26, 2019

Explore the Virtual #CochraneSantiago Programme now!

Thu, 11/21/2019 - 17:52

All content will be freely available on the Colloquium website and open to the entire Cochrane Community of members and supporters!

Cochrane’s annual flagship event brings together the world’s most influential health researchers, scientists, academics, opinion leaders, clinicians, and patients to promote evidence-informed decision-making. We are getting excited to share and interact with Virtual #CochraneSantiago content starting on Monday 2 December - Friday 6 December!

Virtual #CochraneSantiago will highlight the overall theme of ‘Embracing Diversity’, with each day having daily themes. During the week, content will be curated here on our Colloquium website. We have created a dedicated page for each day’s content that will include posters, plenary content, bespoke curated materials from long and short oral presentations as well as pre-produced videos posted ‘as live’ on YouTube each day.

 

We have lots of content to share with you and we invite you to visit the Cochrane Colloquium website daily, join in on conversations on social media using the #CochraneSantiago hashtag, and take part in this unique opportunity to fully embrace the diversity of voices that make up Cochrane’s global community.

 

Monday 2 December: Equity Matters: Cochrane’s Next Frontier
A welcome from the Local Organizing Committee will begin our Virtual Colloquium and two speakers will highlight the importance of equity in Cochrane evidence. Peter Tugwell will discuss Cochrane’s content strategy on equity, and Beibei Yuan will talk about equity analysis in research. Additionally, two presenters will discuss aspects from the new Cochrane Handbook chapter on equity.

Tuesday 3 December: Stakeholder Diversity
Participants can view a recorded webinar regarding the launch of Cochrane's Dissemination Checklist, and Guidance, enabling them to share Cochrane evidence more effectively for use with diverse stakeholders. We’ll also look at how Cochrane is working with patients and their caregivers.

Wednesday 4 December: Methodological Diversity
Multiple speakers will address the importance, and challenge, of incorporating Methodological diversity into Cochrane. Lisa Bero will discuss the importance of making Cochrane evidence relevant for public health practitioners and policy makers; Adrienne Stevens will discuss rapid reviews and the future of this type of review in Cochrane; and Jane Noyes will discuss what the Cochrane Methods Executive are doing to address the importance of methodological diversity. Participants can also watch a recorded webinar introducing the new Cochrane Handbook for Systematic Reviews, as well as presentations by Miranda Cumpston and James Thomas about aspects of the Handbook. There will also be an introductory presentation on RevMan Web, and Cochrane members are encouraged to try out the new Cochrane PICO search BETA on the Cochrane Library! Finally, starting at 11:00 am GMT on Wednesday, Cochrane Crowd is holding a Virtual #CochraneSantiago Challenge to screen 48,000 records in just 48 hours; learn more and get ready to participate!

Thursday 5 December: Looking back
Marking #ThrowbackThursday, this day is a celebration of the last 25 years of Colloquia and focusing on Cochrane’s diverse community of 11,000 members and 70,000 supporters from 130 countries around the world! The Annual General Meeting will be held live from 09:00 to 10:00 am GMT, and members are reminded to register to attend the online meeting. A slideshow of memories from past Cochrane Colloquia will premiere, and a full line-up of 2019's Award and Prize Winners will be recognized and celebrated.

Friday 6 December: Looking ahead
Today, we will turn our focus to 2020 and the next Cochrane Colloquium in Toronto; a video presenting plans for #CochraneToronto will premier, and ways to contribute to and get involved in Cochrane will be highlighted. We will  introduce of new Editor in Chief of the Cochrane Library, Dr. Karla Soares-Weiser, and we'll have the results of the  Cochrane Crowd challenge will end at 11:00 am GMT.

All content will be available for free on the Colloquium website and open to the entire Cochrane Community of members and supporters!

How are you planning on participating? What are you looking forward to the most? Start the conversation today – tell us by using #CochraneSantiago and follow our social media accounts as we get ready for Cochrane’s first-ever Virtual #CochraneSantiago!

Thursday, November 21, 2019

New Cochrane Review assesses different HPV vaccines and vaccine schedules in adolescent girls and boys

Wed, 11/20/2019 - 14:32

New evidence published in the Cochrane Library today provides further information on the benefits and harms of different human papillomavirus (HPV) vaccines and vaccine schedules in young women and men.

HPV is the most common viral infection of the reproductive tract in both women and men globally (WHO 2017). Most people who have sexual contact will be exposed to HPV at some point in their life. In most people, their own immune system will clear the HPV infection.

HPV infection can sometimes persist if the immune system does not clear the virus. Persistent infection with some ‘high-risk’ strains of HPV can lead to the development of cancer. High-risk HPV strains cause almost all cancers of the cervix and anus, and some cancers of the vagina, vulva, anus, penis, and head and neck. Other ‘low risk’, HPV strains cause genital warts but do not cause cancer. Development of cancer due to HPV happens gradually, over many years, through a number of pre-cancer stages, called intra-epithelial neoplasia. In the cervix (neck of the womb) these changes are called cervical intraepithelial neoplasia (CIN). High-grade CIN changes have a 1 in 3 chance of developing into cervical cancer, but many CIN lesions regress and do not develop into cancer. HPV-related cancers accounted for an estimated 4.5% of cancers worldwide in 2012 (de Martel 2017).

Vaccination aims to prevent future HPV infection and the cancers caused by high-risk HPV infection. HPV vaccines are mainly targeted towards adolescent girls because cancer of the cervix is the most common HPV-associated cancer. For the prevention of cervical cancer, the World Health Organization recommends vaccinating girls aged 9-14 years with HPV vaccine using a two-dose schedule (0, 6 months) as the most effective strategy. A three-dose schedule is recommended for older girls ≥15 years of age or for people with human immunodeficiency virus (HIV) infection or other causes of immunodeficiency (WHO 2017).

Three HPV vaccines are currently in use: a bivalent vaccine that is targeted at the two most common high-risk HPV types; a quadrivalent vaccine targeted at four HPV types, and a nonavalent vaccine targeted at nine HPV types. In women, the bivalent and quadrivalent vaccines have been shown to protect against pre-cancer of the cervix caused by the HPV types contained in the vaccine if given before natural infection with HPV (Arbyn 2018).

This Cochrane Review summarizes the results from 20 randomized controlled trials involving 31,940 people conducted across all continents. In most studies, the outcome reported was the production of HPV antibodies by the vaccine recipient’s immune system. HPV antibody responses predict protection against the HPV-related diseases and cancers the vaccines are intended to prevent. Antibody response is often used as a surrogate in HPV vaccine studies because it takes many years for pre-cancer to develop after HPV infection, so it is difficult for studies to follow participants over such long periods of time. Moreover, because trial participants were tested for HPV infection and offered treatment, if HPV-related precancer was found, progression to cervical cancer in this group would be expected to be very low, even without vaccination.

Four studies compared a two-dose vaccine schedule with a three-dose schedule in 2,317 adolescent girls and three studies compared different time intervals between the first two vaccine doses in 2,349 girls and boys. Antibody responses were similar after two-dose and three-dose HPV vaccine schedules in girls. Antibody responses in girls and boys were stronger when the interval between the first two doses of HPV vaccine was longer.

There was evidence from one study of 16 to 26-year old men that the quadrivalent HPV vaccine reduces the incidence of external genital lesions and genital warts compared with a group who did not receive the HPV vaccine.

There was also evidence from a study of 16 to 26-year old women that compared the nonavalent and quadrivalent vaccines that they provide a similar level of protection against cervical, vaginal, and vulval pre-cancerous lesions.

There was evidence from seven studies about HPV vaccines in people living with HIV. HPV antibody responses in children living with HIV were higher after vaccination with either bivalent or quadrivalent vaccine than with a non-HPV control vaccine. These antibody responses against HPV could be maintained up to two years. The evidence about clinical outcomes and harms for HPV vaccines in people with HIV was very limited.

Evidence suggested that up to 90% of males and females who received an HPV vaccine experienced local minor adverse events such as redness, swelling and pain at the injection site. Due to the low rates of serious adverse events in quadrivalent and nonavalent vaccine groups, and the broad definition of these events used in the trials, we cannot really determine the relative safety of different vaccine schedules.

The lead editor of this review and Consultant in Gynaecological Oncology, Musgrove Park Hospital, Somerset, UK, Dr. Jo Morrison said: “We need long-term population-level studies to provide data on the effects of dosing intervals, schedules and vaccines on HPV-related cancers, as well as giving us a more complete picture of rare harms. However, with fewer doses having a similar antibody response, and more extensive evidence from vaccine studies in boys, policy makers are now in a better position to determine how local vaccination programmes can be designed. It would be interesting to see how different schedules and vaccines influence immunisation coverage, but this review, and the studies within it, were not designed to be able to answer that question.”

Read the full review

Full citation: Bergman H, Buckley BS, Villanueva G, Petkovic J, Garritty C, Lutje V, Riveros-Balta AX, Low N, Henschke N. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. 

 

References
WHO 2017
World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017. Weekly Epidemiological Record 2017;92:241–68.
de Martel 2017
de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. International Journal of Cancer 2017;141(4):664–70.
Arbyn 2018
Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews 2018, Issue 5. DOI: 10.1002/14651858.CD009069.pub3

Friday, November 22, 2019

Cochrane in Practice - Dentistry

Wed, 11/20/2019 - 03:02

Cochrane does not make clinical recommendations, instead it provides unbiased and high-quality health evidence so that health decisions, policies, and clinical guidelines can be informed by the best available evidence. ‘Cochrane Evidence in Practice’ series collects stories about clinical professionals using Cochrane evidence - the everyday healthcare professional making sure their patients and clients are getting the best care!

Dental Student Nicole's story:

Name: Nicole Meerah Elango
Position: Second Year Dental Student at Peninsula Dental School
Location: England

Cochrane has been an invaluable resource throughout my higher education journey. During my BSc Biomedical Science and MSc Mental Health degrees, Cochrane reviews remained an integral resource which supplemented my academic work, systematic review and meta-analysis.

I believe that Cochrane produces world-class research based on recent, high-quality evidence. The structured, comprehensive reviews have been instrumental to my clinical education whilst studying BDS Dental Surgery. Remaining up-to-date on the latest, high-quality evidence is essential to developing into a well-rounded dentist and the Cochrane Library has allowed me to do so. I encourage my fellow students to remain updated with the Cochrane Library to ensure we make informed evidence-based treatment decisions with our patients.  

At present, I am contributing to a Cochrane review update. I have also created a research series on Social Media which aims to educate the public and other students about high-quality evidence-based treatment and resources such as The Cochrane Library (see here and here). Feel free to follow and get in touch with me on Instagram: @nicolestudiesteeth

Cochrane does not make clinical recommendations. ‘Cochrane Evidence in Practice’ series collects stories about clinical professionals using Cochrane evidence. Would you  like to add your story of using Cochrane evidence? Please contact mumoquit@cochrane.org to share your story. 

 

 

Wednesday, November 20, 2019

Common Mental Disorders partnership with the Mental Health Foundation

Tue, 11/19/2019 - 19:17

Cochrane Common Mental Disorders works in partnership with the Mental Health Foundation. This partnership helps Cochrane to produce evidence that is relevant to people with everyday lived experience of common mental disorders. Our work with the Mental Health Foundation enables us to better understand what matters to people and to improve the ways we involve people with lived experience in what we are doing. Together we aim to put trusted evidence at the heart of health care decisions for people with common mental disorders.

In June 2019 this partnership was officially launched by hosting an afternoon of debate and discussion at the British Library. Watch a short video about this day below:

You can also watch the Mental Elf live stream of the panel discussion '#MHResearchAndMe Mental health research: What’s in it for us?' here

 

Tuesday, November 19, 2019

Cochrane Indonesia’s 2019 Symposium

Tue, 11/19/2019 - 16:55

Cochrane Indonesia hosted it’s Symposium on 11-17 November 2019, in conjunction with the 2nd International Conference on Clinical Epidemiology.  The theme of the Cochrane Indonesia Symposium was ‘The Role of Evidence Synthesis on Clinical and Health Policy Decisions Making.’ They hosted several workshops and many international speakers including ones from Cochrane Australia, Cochrane Thailand, Cochrane Malaysia, KEMENRISDIKTI, INCLEN, and Universiteit Antwerpen Belgium.  The symposium aimed to provide an international multidisciplinary platform for discussion and debate among health care providers, policy makers, academics, and researchers on contemporary strategies and issues in evidence-informed health care and policy formulation.

 

Tuesday, November 19, 2019

David Sackett Prize awarded to Sir Iain Chalmers

Tue, 11/19/2019 - 14:48

Dr David Sackett was an originator of clinical epidemiology and evidence-based medicine. He contributed extensively to the development of research methods through his books and published articles, as well as through education and lectures at McMaster and around the world. Notably he turned clinical research into a scientifically sound and practical multidisciplinary “team sport,” and has changed for the better the quality of healthcare research and clinical practice. David was the first chair of the Cochrane Collaboration Steering Group in 1993.

This year, the GIMBE Foundation established an award in memory of David, which was presented at The Ecosystem of Evidence conference in November.

The first edition of the prestigious award was assigned to Sir Iain Chalmers by the organisers for;

  • Leading to the development of the Cochrane Collaboration
  • Launching the James Lind Initiative to help people to recognise untrustworthy claims about the effects of treatments
  • His flourishing scientific production: more than 500 papers in peer reviewed journals in the Evidence-Based Health Care (EBHC) field
  • His influential books
  • His courage, shared with Paul Glasziou, in pointing out research waste as a barrier to EBHC
  • Being a maverick: an unusual mix of biting British humour, insatiable intellectual curiosity, and Oxfordian self-composure


 

In a speech of thanks Sir Iain referred to Sackett’s inspired and inspiring leadership of the Evidence-Based Medicine movement, his invaluable contribution as the first chair of the Cochrane Collaboration, and his precious contributions to the James Lind Library.

A summary of the achievements of Sir Iain Chalmers, recognized by the David Sackett Prize is shown here

Tuesday, November 19, 2019

Join Cochrane Crowd for the Cochrane Colloquium Challenge 2019!

Wed, 11/13/2019 - 14:50

Cochrane Crowd are running a citation screening challenge to coincide with the Virtual Cochrane Santiago Colloquium! Help Cochrane Crowd reach 48,000 classifications in 48 hours and be amongst the first to try out the all new, shiny CINAHL task! Details on this and how to join in below.

When is it running?
Start: Wednesday 4th December at 11:00 am GMT
Finish: Friday 6th December at 11:00am GMT
You can check what time that is for you here

How much time do I have to commit?
Of course, we’d love you to do the whole 48 hours! Just kidding. Any contribution is welcomed, whether it be a few five-minute grabs or a more focused effort (so you better make sure you have some screening snacks to hand to keep those energy levels up).

Sounds good so far. But I’m new to Cochrane Crowd. What is it all about?
Your best bet is to watch our 2-minute video introduction here.

What is the new CINAHL task?
For this challenge we want you to help identify possible reports of randomised trials (RCTs) that we have retrieved from a source called CINAHL. We haven’t identified RCTs from this source before. CINAHL is THE source for nursing and allied health professional research.

If I join in, what will I be doing?
Your mission for this challenge is to assess those records from CINAHL and decide whether you think they are describing a randomised trial or not. There will be a brief training module to complete if you haven’t done this kind of task before task before. Once identified, these studies go into a central register where health researchers and practitioners can access them.

Will there be prizes?
Of course! We’re glad you asked! Yes, prizes will go to the top three contributors. What are the prizes, you ask? A snazzy (limited edition!) T-shirt and a highly readable book – it’ll be like Christmas come early!

How do I sign up for the challenge?
There is no need to sign up for the challenge per se. You can just head to Cochrane Crowd anytime during the 48 hours of the challenge and get cracking!  If you’ve not been to Cochrane Crowd before, then you can sign up here.

Sounds fun, can I tell all my friends about it and get them to join in?
Yes please! We want as many as possible to join us. Feel free to share this page (share buttons below).

Is there a Twitter hashtag?
Sure is, we’ll be keeping in touch with #ColloquiumChallenge2019

How can I find out more?
You can email Emily and Anna from Cochrane Crowd at crowd@cochrane.org. And don’t forget to follow us on Twitter!

 

Wednesday, November 13, 2019

Join our virtual #CochraneSantiago, 2 - 6 December 2019…here’s how you can participate

Tue, 11/12/2019 - 02:14

v\:* {behavior:url(#default#VML);} o\:* {behavior:url(#default#VML);} w\:* {behavior:url(#default#VML);} .shape {behavior:url(#default#VML);}

We are delighted to announce our plans for Cochrane’s Virtual #CochraneSantiago which will be held online from 2-6 December 2019 and open to ALL Cochrane members and supporters.

Cochrane’s annual flagship event brings together the world’s most influential health researchers, scientists, academics, opinion leaders, clinicians, and patients to promote evidence-informed decision-making.

Whilst the recent, unprecedented situation of civil unrest across Santiago led to the cancellation of our face-to face Colloquium this year, with the support of so many contributors, we are pleased to welcome the full community to participate in Cochrane’s first, virtual #CochraneSantiago Colloquium.  Whilst we recognize our virtual meeting can never replace what we would have achieved together in-person in Chile, we believe that this unique week of content will be a fitting tribute to recognizing the extraordinary efforts of hundreds of contributors and Cochrane community‘s spirit of resilience and collaboration.

Virtual #CochraneSantiago will highlight the theme of ‘Embracing Diversity’. During the week of 2-6 December, content will be curated on our Colloquium website. We have created a dedicated page for each day’s content that will include posters, plenary content, bespoke curated materials from long and short oral presentations as well as pre-produced videos posted ‘as live’ on YouTube each day. In addition, we will provide ways you can interact with our daily content including discussion questions and social media conversations; and, we look forward to hearing from you on the wide-ranging discussions happening on Twitter, Facebook, and Instagram using #CochraneSantiago, with Cochrane’s Content Creators helping to lead these conversations across our web platforms.

The Virtual Colloquium is an open invitation to all - whether you registered and were planning to travel to Santiago or not! More details on the final programme schedule and how you can get involved each day will be posted here soon.

We look forward to welcoming you and hope it’ll be a unique opportunity to fully embrace the diversity of voices that make up Cochrane’s global community.

Hold the date now - Monday 2- Friday 6 December 2019 for virtual #CochraneSantiago!

Tuesday, November 12, 2019

Cochrane supports AllTrials report on UK clinical trial transparency used as a basis for parliament evidence session

Fri, 11/08/2019 - 12:11

Cochrane recently supported an AllTrials report updating the UK House of Commons Science and Technology Select Committee on rates of clinical trial reporting among universities and NHS trusts.

The report, which used data from the EU Trials Tracker, updated the Committee on progress since it wrote to UK universities and NHS trusts in January 2019 urging them to fulfil their reporting requirement within six months.

Under the European Commission’s Clinical Trial Regulation, trial sponsors must post summary results to the EU Clinical Trials Register within one year of a study ending, or six months for paediatric trials.

Figures from the report show an overall improvement in the publishing of results for UK university- and NHS trust-sponsored trials – rising from 48.1% in January 2019 to 63.9% in October 2019. However, while some sponsors went from 0% to 100% during this period, 33 NHS trusts and 6 universities had 0% of their trial results posted.

The Committee used the report as a basis for an evidence session at Parliament which took place on 29 October. Stakeholders, including universities, NHS trusts and regulators, were questioned about reporting rates, and there was discussion about the action that needs to be taken to achieve 100% compliance in the UK.
Cochrane Editor in Chief, Dr Karla Soares-Weiser, said:

“At Cochrane, we rely on the availability of clinical trial data to produce high-quality and relevant systematic reviews. We welcome this effort among UK-based non-commercial clinical trial sponsors to improve reporting rates – though there is still clearly much more to be done for all sponsors to meet their full ethical obligations and achieve 100% compliance.

Given that this issue goes far beyond the UK, we think it’s time for similar coordinated action on clinical trial transparency in other countries. We encourage researchers, healthcare professionals, patients and members of the public to get involved and to hold clinical trial sponsors to account on their reporting rates.”

Friday, November 8, 2019

The Recommended Dose podcast: Dr Arnav Agarwal, recently graduated doctor

Wed, 11/06/2019 - 14:52

Recently graduated doctor

This week, Dr Arnav Agarwal joins Ray to share the perspective and experiences of a young, recently graduated doctor working in a busy, metropolitan hospital. Despite the long shifts and demanding environment, Arnav makes time and space to reflect on work, life and mortality through his thought-provoking poetry and volunteer work.

Listen to Recommended Dose podcasts on SoundCloud, iTunes, Stitcher  or wherever you listen to your favourite podcasts. 

Find more details and our show notes the podcast page or follow on twitter  or facebook.

The Recommended Dose is produced by Cochrane Australia and co-published with The BMJ.

Wednesday, November 13, 2019

Podcast: Methods to help people quit smoking

Mon, 11/04/2019 - 10:22

Cochrane podcasts deliver the latest Cochrane evidence in an easy to access audio format, allowing you to stay up to date on newly published reviews wherever you are. Each Cochrane podcast offers a short summary of a recent Cochrane review from the authors themselves. They are brief, allowing everyone from healthcare professionals to patients and families to hear the latest Cochrane evidence in under five minutes. Here we have curated three recent Cochrane podcasts on the subject of quitting smoking.

Podcast: What is the best way to use nicotine replacement therapy to quit smoking?

Nicotine replacement therapy has been used to help people stop smoking for more than 20 years, and a large and growing body of research has tested it. To help cope with this, some of the related Cochrane Reviews have been divided up and in April 2019 the evidence on different doses, durations and modes of delivery was updated into a new review. Here’s one of the authors, Samantha Chepkin from Cochrane UK to tell us what they found.

Podcast: Can rewards help smokers to quit in the long term?

Smoking is still the biggest cause of preventable death worldwide and there are more than 50 Cochrane Reviews of the effects of interventions to help people quit. One of these, on the use of incentives, which was last published in 2015 was updated in July 2019. We asked the new lead author, Caitlin Notley, from the University of East Anglia in the UK to bring us up to date with the evidence.

Read the Cochrane Featured Review

Podcast: Does motivational interviewing help people to quit smoking?

Smoking remains a substantial public health problem around the world and the search for effective ways to help people stop is ongoing, with more than 50 Cochrane Reviews providing evidence on a wide variety of interventions. One of these reviews, on motivational interviewing, was updated in July 2019 and the lead author, Nicola Lindson from the University of Oxford in the UK brings us up to date in this podcast.

Monday, November 4, 2019

The Recommended Dose with Marion Nestle, one of the world's most powerful foodies

Fri, 11/01/2019 - 11:30

Professor Marion Nestle

This week, Ray ventures into the notoriously complex field of nutrition with special guest, Professor Marion Nestle. Named by Forbes as one of the world's most powerful foodies, Marion’s stellar career spans five decades of research, teaching, advocacy work and the publication of countless prize-winning books.

Listen to Recommended Dose podcasts on SoundCloud, iTunes, Stitcher  or wherever you listen to your favourite podcasts. 

Find more details and our show notes the podcast page or follow on twitter  or facebook.

The Recommended Dose is produced by Cochrane Australia and co-published with The BMJ.

Thursday, November 7, 2019

Pages